Radiopharm Theranostics Ltd
RADX4.905USD
-0.120-2.41%
Close 06/06, 16:00（ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Radiopharm Theranostics Ltd Company
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Company Info
Company codeRADX
Company nameRadiopharm Theranostics Ltd
IPO dateNov 25, 2021
Founded at2021
CEOMr. Riccardo Canevari
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
AddressLevel 3
CityMELBOURNE
Stock exchangeNASDAQ Capital Market Consolidated
CountryAustralia
Postal code3053
Phone61398245254
Websitehttps://radiopharmtheranostics.com/
Company codeRADX
IPO dateNov 25, 2021
Founded at2021
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Executive Officer, Company Secretary
Chief Financial Officer, Executive Officer, Company Secretary
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
SilverArc Capital Management, LLC
2.41%
Regal Partners Limited
1.17%
Regal Funds Management Pty. Ltd.
1.17%
Affinity Asset Advisors LLC
0.83%
Other
94.42%
Shareholder Statistics
Shareholder
Proportion
SilverArc Capital Management, LLC
2.41%
Regal Partners Limited
1.17%
Regal Funds Management Pty. Ltd.
1.17%
Affinity Asset Advisors LLC
0.83%
Other
94.42%
Type
Shareholder
Proportion
Hedge Fund
4.41%
Investment Advisor
1.17%
Other
94.42%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
5
526.71K
6.77%
+526.71K
2024Q4
5
526.71K
6.77%
+526.71K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SilverArc Capital Management, LLC
187.41K
2.41%
+187.41K
--
Dec 31, 2024
Regal Partners Limited
90.91K
1.17%
+90.91K
--
Dec 31, 2024
Regal Funds Management Pty. Ltd.
90.91K
1.17%
+90.91K
--
Dec 31, 2024
Affinity Asset Advisors LLC
156.17K
2.01%
+156.17K
--
Dec 31, 2024
UBS Financial Services, Inc.
1.32K
0.02%
+1.32K
--
Dec 31, 2024
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
